1. Background {#sec1}
=============

Currently, 1.7 million children are living with human immunodeficiency virus (HIV) and over 90% of them live in sub-Saharan Africa \[[@B1], [@B2]\]. Ethiopia has the largest population of HIV-infected children in the region. According to an estimate by the Federal HIV/AIDS Prevention and Control Office (FHAPCO), there are over 738,976 people living with HIV/AIDS in Ethiopia \[[@B3]\]. Of these, 178,500 are children younger than 15 years of age \[[@B4]\].

The initiation of potent antiretroviral therapy (ART) in the mid-1990s has dramatically reduced HIV-associated morbidity and mortality \[[@B5]--[@B8]\]. Antiretroviral therapy reduces HIV-associated morbidity and mortality by suppressing HIV replication to undetectable levels and providing a consistent increase in the number of CD4+ T lymphocytes \[[@B9], [@B10]\]. The resulting effect is the recovery of the immune system, and thus, immune reconstitution is an important outcome measure of ART \[[@B11]\]. According to the recent report, 59% of children living with HIV were on treatment in Ethiopia \[[@B12]\].

The earlier World Health Organization (WHO) guidelines recommended using a nucleoside reverse transcriptase inhibitor (NRTI) backbone including a thymidine analogue stavudine (d4T) or zidovudine (AZT) together with lamivudine (3TC) for paediatric HIV treatment \[[@B13]\]. But in 2010, the WHO guideline discouraged the use of d4T because of high lipodystrophy rates in adults and adolescents \[[@B14]\]. As a result, the current guidelines were changed to recommend substitution of the thymidine analogue with abacavir (ABC) depending on studies which reported fewer side effects and improved virological responses with ABC compared to d4T or AZT \[[@B15], [@B16]\].

In Ethiopia, the initial ART regimen included the use of d4T as a preferred first-line NRTI for paediatric HIV treatment. In 2012, Ethiopia implemented the d4T phase-out program, and ABC became routinely used as a standard of care \[[@B17]\]. Currently, both ABC- and AZT-based regimens are routinely utilized. However, there is a lack of study regarding the immunological response of ABC- and AZT-containing regimens among HIV-infected children in Ethiopia. Studies conducted in some African children \[[@B18]--[@B21]\] showed an encouraging and comparable immunologic response to those obtained among children in well-resourced countries \[[@B11], [@B22], [@B23]\]. In this study, we compared the immunological response and associated factors in a cohort of HIV-infected children receiving ABC- and AZT-containing regimens.

2. Methods {#sec2}
==========

2.1. Study Design and Setting {#sec2.1}
-----------------------------

A retrospective hospital-based cohort study was conducted on HIV-infected children in Jimma Medical Center (JMC). JMC is located in Jimma town, 355 km from Addis Ababa. It is currently the only teaching and specialized hospital in the Southwest region of Ethiopia. The hospital serves as a referral site and provides specialized care for Southwest Ethiopia with a catchment population of about 15 million. The study was conducted from April 10 to May 10, 2017, by including data from November 2015 to April 2017.

2.2. Study Population and Variables {#sec2.2}
-----------------------------------

We included HIV-infected children (\<15 years) who were on ABC- and AZT-based regimens that fulfill the eligibility criteria. Patients on ABC- and AZT-based first-line regimens, having at least six months of follow-up with good adherence, whose records were legible and complete, who have CD4 count at least at the baseline and six months, and younger than 15 years were included in the study. Those transferred out within \<6 months of follow-up and patients with incomplete records were excluded. The study was conducted by dividing the total sample into two major classes as ABC group and AZT group.

Data were collected on sociodemographic characteristics (age, sex, area of residence, weight (kg), height (cm), and body mass index (BMI)), HIV-related factors (CD4 count and WHO clinical stage), treatment-related factors (types of ART regimen, opportunistic infection (OI) prophylaxis (cotrimoxazole preventive therapy (CPT) and isoniazid preventive therapy (IPT)), and antitubercular treatment), and immunological response (CD4+change).

2.3. Sample Size Determination {#sec2.3}
------------------------------

The number of patients who fulfilled the eligibility criteria for the ABC group was 87 and all of them were included. From those on AZT-based regimen, 92 eligible patients were included, making ABC-to-AZT group ratio of 1 : 1.05. Finally, a total of 179 subjects, with 87 charts of patients from the ABC group and 92 patients from the AZT group were reviewed.

2.4. Sampling Technique {#sec2.4}
-----------------------

Since the number of patients on ABC-based regimen was limited, we included all eligible patients. A simple random sampling technique was used to select 92 patient charts for AZT-based regimens using a computer-generated random number.

2.5. Data Collection Procedure and Quality Assurance {#sec2.5}
----------------------------------------------------

Data on socio-demographic, clinical, laboratory, and drugs administered were collected by record review using English version checklists. The data collection tool was carefully prepared after reviewing relevant literature studies to enable the data collectors to gather all the information required to address the study objectives. A 2-day training was provided on the data collection tool and general procedures for data collectors, i.e., 2 pharmacists (B. Pharm) and 2 nurses. Data from antiretroviral drugs and patient information sheet were collected by pharmacists, and data from ART clinic intake form, HIV care/ART follow-up, and patient sheet were collected by the nurses. The baseline body mass index of the subjects was later calculated after collection of baseline height and weight of the patient from the patient chart. Pretest was conducted on 5% of the eligible records.

2.6. Operational Definition of Terms {#sec2.6}
------------------------------------

  Good adherence: estimated adherence level of \>95% \[[@B24]\] as recorded by ART physicians/nurses  Child: age \<15 years \[[@B25]\]  Lost to follow-up: refer to a patient who has missed clinical or drug pickup appointments permanently \[[@B26]\].

2.7. Ethical Consideration {#sec2.7}
--------------------------

The study was approved by the Institutional Review Board (IRB) of Jimma University. It has designated with an IRB number of IHRPGB/112/2017. The need for informed consent was waived because of the retrospective, anonymous nature of the study. During data collection, confidentiality was ensured, and for this reason, the name and address of the patient were not recorded in the data collection checklist.

2.8. Statistical Analysis {#sec2.8}
-------------------------

Data were double-entered into Epi-Data and exported to STATA 13.1 for cleaning and analysis. Descriptive analysis was performed, and results were presented in text, tables, and charts. Bivariate and multivariate mixed-effects linear regressions for repeated measurements were performed to assess the adjusted effect of the ART regimen and identify additional predictors of CD4+ recovery. The coefficient of mean CD4+ count with 95% confidence intervals was used as a measure of the strength of association, and *P* \< 0.05 was considered to declare a statistical significance. Marginal analysis was also conducted to see the difference among the specific regimen category.

3. Results {#sec3}
==========

3.1. Overview of the Study Participants {#sec3.1}
---------------------------------------

During the study period, a total of 367 patients started antiretroviral therapy (ART) and were treated for at least 6 months. Of these, 108 from ABC group and 212 from AZT group have a complete CD4+ count at the 6^th^month of treatment. Thirty-two patients were excluded initially from either regimen due to missed CD4+ count at 6 months and 30 (21 and 9 from ABC and AZT, respectively) because of the adherence problem, and 179 patients were included in the analysis ([Figure 1](#fig1){ref-type="fig"}).

The mean ± standard deviation (SD) duration of follow-up was 939.8 + 478.3 and 984.92 + 453.1 days for the ABC and AZT groups, respectively. During the study period, a total of 4 patients (1 (1.14%) patient from the ABC group and 3 (3.3%) from the AZT group; *P*=0.339) died.

3.2. Baseline Socio-Demographic and Clinical Characteristics {#sec3.2}
------------------------------------------------------------

We included 179 patients, of whom 98 (54.75) were females. One hundred forty (78.2%) of the patients had a BMI of less than fifth centile, and there was a statistically significant difference between groups (*P* = 0.03). Baseline socio-demographic and clinical characteristics of the study participants are depicted in [Table 1](#tab1){ref-type="table"}.

3.3. Immunological Response {#sec3.3}
---------------------------

The overall change in the mean standard deviation (±SD) of CD4+ lymphocyte count was 139.3 (±55.7) cells/mm^3^ for the ABC group and 150.5 (±42.1) cells/mm^3^ for the AZT group. The mean change in CD4+ lymphocyte count from baseline for the past 18 months was presented comparatively in [Figure 2](#fig2){ref-type="fig"}. The SDs are 55.3 vs. 41.6, 66.3 vs. 63.1, and 87.7 vs. 65.1 at 6^th^, 12^th^, and 18^th^ months for ABC- and AZT-based regimens, respectively.

As shown in the figure, the CD4+ lymphocyte count trajectory belonging to AZT-based regimen looks steeper after the first 6 months of therapy.

Patients on AZT + 3TC + NVP had the highest baseline CD4+ lymphocyte count, followed by AZT + 3TC + LPV/r and ABC + 3TC + NVP. The lowest baseline CD4+ count was recorded for ABC + 3TC + LPV/r ([Table 2](#tab2){ref-type="table"}).

3.4. Predictors of CD4+ Lymphocyte Count Change {#sec3.4}
-----------------------------------------------

We conducted a mixed-effect linear regression using a consecutive CD4+ lymphocyte count measured over the past 18 months as an outcome variable. The slope of random-effect linear regression was used to report the overtime change in CD4+ count attributed to the predictor variables. The overall average gain in CD4+ count every six months was 53.0 cells/mm^3^ (*P* \< 0.001 and 95% CI \[46.86--59.20\]) with an interclass correlation coefficient of 65.5% (*P* \< 0.001). This implies a significant proportion of variability in CD4+ lymphocyte count change due to patient-specific factors. Among the groups, 36.73% of the variation in CD4+ lymphocyte change variability was explained by differences in ART regimens (*P* \< 0.001).

Body mass index, weight for height, ART group, baseline, CD4+ lymphocyte count, occurrence of opportunistic infections (OIs), WHO clinical staging, viral load, nutritional status, and exposure to antitubercular drugs were associated with CD4+ lymphocyte count change on binary linear regression. After adjusting for all confounders, ART group, baseline CD4+ lymphocyte count, WHO clinical stages, and viral load remained independent predictors for CD4+ lymphocyte count change.

Therefore, patients who commenced on AZT-based regimens had a significant change in CD4+ lymphocyte count at each visit. Accordingly, patients exposed to AZT-based regimens had 20.51 cells/mm^3^ CD4+ count advantage every six months (*β* = 20.51, 95% CI \[6.37--34.65\]). Each unit increment in baseline CD4+ count will contribute to 0.55 cells/mm^3^ CD4 gain every half year (*β* = 0.55, 95% CI \[0.49--0.69\]).

On the contrary, patients with WHO stages III and IV were in a precarious situation in terms of their CD4+ count recovery. Every six months, patients with WHO stage III and WHO stage IV had 47.61 and 73.54 CD4+ lymphocyte count disadvantages, respectively (*β* = −47.61\[−84.27− (−10.96)\] and *β* = −73.54\[−118.27− (−28.81)\]). In addition, patients with a viral load of \>1000 copies/ml had 28 CD4+ lymphocyte count disadvantages every half year (*β* = −27.68\[−47.75− (−7.61)\]) ([Table 3](#tab3){ref-type="table"}).

3.5. Postestimation Treatment Effects {#sec3.5}
-------------------------------------

We also conducted a marginal analysis to predict the changes in the mean CD4+ lymphocyte counts associated with each regime and to identify the regimen with the lowest performance. Therefore, except ABC + 3TC + NVP, the other two ABC-based regimens, namely, ABC + 3TC + EFV and ABC + 3TC + LPV/r, deemed to be the lowest performing regimens as compared to their AZT counterparts. Accordingly, the predicted mean CD4+ count for paediatrics treated with AZT + 3TC + NVP had 318.3 cells/mm^3^ of CD4+ lymphocyte count change, and it was 296.33 cells/mm^3^ CD4+ for those treated with ABC + 3TC + EFV. The change is statistically significant in either case (*P* \< 0.001). The regimen AZT + 3TC + LPV/r tended to have an excellent predicted CD4+ lymphocyte count change relative to all other regimens, while ABC + 3TC + LPV/r performed the opposite (margins 338.0 cells/mm^3^ versus 249.13 cells/mm^3^ (*P* \< 0.001)) ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

This study was the first ever to compare the immunological response of ABC- and AZT-based regimens among HIV-infected children in Ethiopia. The biannual analysis of mean CD4+ gain showed that the maximum gain in mean CD4+ count was attained with AZT + 3TC + LPV/r, while ABC + 3TC + LPV/r had the least immunologic recovery over the entire treatment course. The CD4+ lymphocyte count trajectory showed a linear trend. Baseline CD4+ lymphocyte count, ART group, WHO clinical stages, and viral load were independent predictors for CD4+ changes over time.

Our finding of mean CD4+ recovery was inconsistent with a randomized open-label study by Mulenga et al. \[[@B27]\], where a comparable immunologic response was achieved between AZT- and ABC-containing regimens. A study by Cassim et al. \[[@B28]\] also failed to show a significant difference in terms of immunologic response between ART regimens. The higher CD4+ recovery with AZT-based regimens in this study might be due to a higher baseline CD4+ count of those patients who were on AZT-containing regimens ([Table 1](#tab1){ref-type="table"}). In addition, the difference in the study design might contribute to the variation. This is thus an additional evidence to advocate to the test and treat strategy as opposed to waiting for dropping of CD4 counts at lower thresholds \[[@B24]\]. The finding from the marginal analysis also indicated that the change in mean CD4+ count is significantly higher in AZT-based regimens. Adult immunologic studies indicated that a linear trend in CD4+ increment at the early phase of therapy is expected and it became flat with minimal CD4+ gain later after 18^th^ month of treatment course \[[@B29]\]. However, the linear trend of immunologic recovery may indicate our study was ended prematurely.

The overall random-effect linear regression analysis had pointed out that baseline CD4+ lymphocyte count, ART group, WHO clinical stages, and viral load were independent predictors for CD4+ change overtime.

The marginal effects of each regimen confirmed that the immunologic outcome associated with AZT+3TC + LPV/r (margins = 338.0 cells/mm3/, *P* \< 0.001) was the most favorable followed by ABC+3TC + NVP (*m* = 337.8 cells/mm3, *P* \< 0.001) and AZT + 3TC + EFV (*m* = 320.3, *P* \< 0.001). However, ABC+3TC + LPV/r had the lowest predicted change in CD4+ count (*m* = 249.13, *P* \< 0.001), implying minimal immunologic response, and further study is needed to clarify this finding.

Patients who commenced on AZT-based regimens had greater CD4+ improvement over time. Accordingly, those patients who had exposed to AZT-based regimens were associated with an average CD4+ count advantage of 20.51 cells/mm^3^ (*β* = 20.51, 95% CI \[6.37--34.65\]). This finding is inconsistent with the Paediatric European Network for the Treatment of AIDS (PENTA 5) study, where children on ABC-based regimens had better immunologic response as compared to AZT-containing regimens \[[@B30]\]. This variation might be due to differences in study design (RCT vs. retrospective), study setup, and sample size.

In the cohort, baseline CD4+ count was another positive predictor for successful immunologic recovery. Therefore, each unit increment in the baseline CD4+ count will contribute to 0.55 cells/mm^3^ CD4 gain every half year (*β* = 0.55, 95% CI \[0.49--0.69\]). This is concurrent with previous studies \[[@B31]--[@B34]\], in which a higher baseline CD4+ lymphocyte count was associated with better immunologic response. This could be due to less extensively depleted immune system, which will be boosted easily after initiation of ART. It is also in agreement with the current WHO ART guidelines \[[@B35]\], which recommends the initiation of ART at diagnosis (test and treat) regardless of CD4+ count and WHO stage.

On the contrary, patients with WHO stages III and IV were in a precarious situation in terms of their CD4+ count recovery. Every six months, patients with WHO stage III and WHO stage IV had 47.61 and 73.54 CD4+ lymphocyte count disadvantage, respectively (*β* = −47.61\[−84.27− (−10.96)\] and *β* = −73.54\[−118.27− (−28.81)\]). This is in agreement with studies conducted in Nigeria \[[@B36]\] and Tanzania \[[@B37]\], in which advanced clinical stage was associated with worse CD4+ recovery. Similar observation was also reported by Kaufmann et al. \[[@B38]\], in which patients with advanced HIV stage had poor immune recovery compared to those in the early stage of the disease. This finding suggests that patients with advanced HIV/AIDS and profound immune suppression need special attention to improve their outcome. Similarly, patients with a viral load of \>1000 copies/ml had a worse immunologic response (*β* = −27.68\[−47.75− (−7.61)\]). This finding is consistent with the study conducted by Zhou et al. \[[@B39]\].

This study had several possible limitations. Firstly, because of the retrospective nature of the study, we were not able to capture some important data such as adverse drug effects of ART. Second, as the sample size was relatively small, the power to detect definitive differences may have been limited. It was a single-site hospital-based study, and therefore, the findings may not be generalizable to the general population, and measures of adherence by health professionals that may not fit the reality are some of the limitations.

5. Conclusion {#sec5}
=============

In the current study, patients with AZT + 3TC + LPV/r had a better immunologic recovery. Immunologic response was described worse in patients with a viral load of \>1000 copies/ml, low baseline CD4+ count, advanced WHO clinical stages, and ABC-containing regimens. Further study is needed to clarify these aspects.
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###### 

Comparative baseline characteristics of the cohort at JMC, from April 10 to May 10, 2017.

  All *n* = 179              ABC group (*n* = 87)   AZT group (*n* = 92)   *P* value    
  -------------------------- ---------------------- ---------------------- ------------ -------
  Sex                        Male                   42 (48.3%)             39 (42.4%)   0.42
  Female                     45 (51.7%)             53 (57.6%)                          
                                                                                        
  Age (years)                \<3 years              11 (12.6%)             12 (13.0%)   0.97
  3--5 years                 18 (20.7%)             20 (21.7%)                          
  \>5 years                  58 (66.7%)             60 (65.2%)                          
                                                                                        
  BMI (baseline)             \<5^th^ centile        74 (85.0%)             66 (71.7%)   0.03
  \>5^th^ centile            13 (14.9%)             26 (28.3%)                          
                                                                                        
  Maternal HIV status        Positive               78 (89.7%)             83 (90.2%)   0.91
  Unknown                    9 (10.3%)              9 (9.8%)                            
                                                                                        
  Area of residence          Urban                  66 (75.9%)             68 (73.9%)   0.76
  Rural                      21 (24.1%)             24 (26.1%)                          
                                                                                        
  Baseline CD4+ (mean +SD)   166.31 + 76.223        178.78 + 71.12         0.26          
                                                                                        
  WHO stage                  I                      8 (9.2%)               3 (3.3%)     0.08
  II                         24 (27.6%)             40 (43.5%)                          
  III                        45 (51.7%)             42 (45.7%)                          
  IV                         10 (11.5%)             7 (7.6%)                            
                                                                                        
  Functional status          W/A                    72 (82.8%)             88 (95.7%)   0.001
  A/D                        12 (13.8%)             0                                   
  B/r                        3 (3.4%)               4 (4.3%)                            
                                                                                        
  TB (treatment)             Yes                    3 (3.4%)               9 (9.8%)     0.06
  No                         84 (96.6%)             83 (90.2%)                          
                                                                                        
  OI prophylaxis             Both CPT and INH       85 (97.7%)             89 (96.7%)   0.69
  CPT only                   1 (1.1%)               1 (1.1%)                            
  Neither                    1 (1.1%)               2 (2.2%)                            
                                                                                        
  Nutritional status         Normal                 45 (51.7%)             57 (62.0%)   0.17
  SAM                        42 (48.3%)             35 (38.0%)                          

###### 

CD4+ lymphocyte count at different points of time with respect to each regimen.

  Regimen                         At baseline      6 months       12 months      18 months
  ------------------------------- ---------------- -------------- -------------- ---------------
  ABC + 3TC + LPV/r, mean (±SD)   133.0 (8.01)     94.4 (14.18)   165.7 (21.9    162.83 (56.4)
  ABC + 3TC + EFV                 171.2 (5.59)     95.2 (6.80)    142.59 (9.9)   195.10 (18.4)
  AZT + 3TC + NVP                 221.0 (9.16)     68.6 (20.86)   116.3 (22.6)   135.3 (17.6)
  AZT + 3TC + LPV/r               191.67 (10.83)   91.2 (10.2)    161 (14.4)     217.6 (11.0)
  AZT + 3TC + EFV                 174.2 (4.88)     95.1 (4.98)    165.4 (8.4)    197.3 (10.2)
  ABC + 3TC + NVP                 186.8 (11.95)    99 (22.58)     145.8 (25.1)   208.2 (31.1)

###### 

Random-effect linear regression analysis of trend of CD4+ count (slope, cells/mm^3^/6 month) at JMC, from April 10 to May 10, 2017.

  Variables              *n* (%)               Unadjusted %*β* \[95%CI\]       *P* value                   Adjusted %*β* \[95%CI\]       *P* value               
  ---------------------- --------------------- ------------------------------- --------------------------- ----------------------------- ----------------------- --------
  Sex                    Male                  98 (54.75)                      0                                                                                  
  Female                 81 (45.25)            7.46\[−13.61−28.53\]            0.488                                                                             
                                                                                                                                                                 
  Age: median (IQR)      7 (4--9)              179 (100)                       −0.56\[−4.24−3.12\]         0.765                                                  
                                                                                                                                                                 
  BMI                    Below 5^th^ centile   140 (78.21)                     −19.45\[−44.56−5.70\]       0.130                         −5.18\[−22.99−12.63\]   0.569
  Above 5^th^ centile    39 (21.79)            0                                                           0                                                     
                                                                                                                                                                 
  Weight for height      ≤70%                  36 (20.11)                      −31.84\[−57.96− (−5.72)\]   0.017                         2.31\[−18.10−22.72\]    0.825
  70--85%                14 (7.82)             −9.84\[−48.62−28.94\]           0.619                       5.91\[−21.17−32.99\]          0.669                   
  ≥85%                   129 (72.07)           0                                                           0                                                     
                                                                                                                                                                 
  In care of the child   Mother                24 (13.41)                      16.91\[−13.74−47.57\]       0.280                                                  
  Others                 155 (86.59)           0                                                                                                                 
                                                                                                                                                                 
  Maternal status        Dead                  33 (18.44)                      −3.244\[−30.53−24.06\]      0.816                                                  
  Live                   146 (8156)            0                                                                                                                 
                                                                                                                                                                 
  Maternal serostatus    Unknown               18 (10.06)                      −5.01\[−40.54−30.53\]       0.782                                                  
  Negative               161 (89.94)           0                                                                                                                 
                                                                                                                                                                 
  Paternal status        Dead                  47 (26.26)                      0.32\[−23.39−24.03\]        0.979                                                  
  Live                   132 (73.74)           0                                                                                                                 
                                                                                                                                                                 
  Residence              Urban                 134 (78.86)                     0                                                                                  
  Rural                  45 (25.14)            −6.59\[−31.04−17.87\]           0.598                                                                             
                                                                                                                                                                 
  ART group              ABC                   87 (48.60)                      0                                                         0                        
  AZT                    92 (51.40)            30.42\[9.89--50.94\]            0.004                       20.51\[6.37−34.65\]           0.004                   
                                                                                                                                                                 
  CD4 count              162 (117--221)        179 (100)                       0.72\[0.62--0.82\]          ≤0.001                        0.55\[0.49−0.69\]       ≤0.001
  OI occurred            No                    121                             0                                                         0                        
  Yes                    58                    −49.12\[−70.49− (−27.74)\]      ≤0.001                      −18.65\[−5.49−42.78\]         0.130                   
                                                                                                                                                                 
  Viral load             ≤1000 copies/ml       146 (83.43)                     0                                                                                  
  \>1000 copies/ml       29 (16.57)            −50.21\[−77.71− (−22.71)\]      ≤0.001                      −27.68\[−47.75− (−7.61)\]     0.007                   
                                                                                                                                                                 
  WHO stage              Stage I               11 (6.15)                       0                                                         0                        
  Stage II               64 (35.75)            −31.43\[−73.23−10.37\]          0.141                       −28.63\[−64.05−6.71\]         0.112                   
  Stage III              87 (48.60)            −94.64\[−136.08− (−53.19)\]     ≤0.001                      −47.61\[−84.27− (−10.96)\]    0.011                   
  Stage IV               17 (9.50)             −151.41\[−199.26− (−103.56)\]   ≤0.001                      −73.54\[−118.27− (−28.81)\]   0.001                   
                                                                                                                                                                 
  Nutritional status     Normal                102 (57.00)                     0                                                         0                        
  SAM                    77 (43.00)            −38.79\[−59.28− (−18.30)\]      ≤0.001                      −13.42\[−35.34−8.50\]         0.230                   
                                                                                                                                                                 
  TB treatment           No                    166 (92.74)                     0                                                         0                        
  Yes                    13 (7.26)             −61.14\[−103.84− (−18.43)\]     0.005                       −32.58\[−65.18−0.21\]         0.050                   

###### 

The predicted CD4+ lymphocyte count change of paediatric patients receiving ABC- and AZT-based regimens at JMC.

  ART regimens        Delta method   *t*     *P* value   95% CI         
  ------------------- -------------- ------- ----------- -------------- ----------------
  AZT + 3TC + NVP     318.3          25.38   12.54       *P* \< 0.001   268.38--368.17
  AZT + 3TC + EFV     320.3          6.40    50.05       *P* \< 0.001   307.73--332.89
  AZT + 3TC + LPV/r   338.0          14.23   23.76       *P* \< 0.001   310.03--365.97
  ABC + 3TC + NVP     337.8          21.73   15.54       *P* \< 0.001   295.07 380.53
  ABC + 3TC + EFV     296.33         7.22    41.05       *P* \< 0.001   282.14--310.52
  ABC + 3TC + LPV/r   249.13         15.12   16.48       *P* \< 0.001   219.41--278.85
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